Edwards' Sapien TAVI device closer to US approval with positive FDA report
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences looks ever closer to achieving its goal of launching its Sapien heart valve system in the US this year, after FDA reviewers issued a positive report on the safety and efficacy data of the device. The report should work in Edwards' favour tomorrow (20 July) when Sapien comes under scrutiny by the agency's advisory panel – a recommendation by the panel could help the firm clinch final premarket approval for Sapien, making it the first transcatheter aortic valve implantation (TAVI) system to hit the US.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.